Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Numerous organizations are cancelling or postponing activities that involve large groups of people.
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.
The company’s founder and chief executive officer, Ravi Srinivasan, took time to speak with BioSpace to discuss the company and its technology platform.
According to reports, 15 employees who attended a management meeting in Boston have now tested positive for the virus.
Mutual expertise drives innovations to address supply issues for vaccines for outbreak pathogens
For the past four years, the Gloucester Marine Genomics Institute has been leading the charge training workers for a future in the biotech industry through its Biotechnology Academy.
The stated cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
According to a company statement, the three employees are doing well and “improving under the care of their healthcare providers.”
Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week’s Movers & Shakers.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.